Lupus & antiphospholipid syndrome
Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials
Pooled result · Reduction of ≥ 4 points from baseline in SLEDAI-2K scoreResult — go to the resultOdds ratio 1.407 95% CI 1.123–1.763Authors' conclusion
Meta-analysis reveals that baricitinib 4 mg is beneficial for treating active SLE in terms of a reduction of ≥ 4 points from baseline in SLEDAI-2K score and SLEDAI-2K remission of arthritis or rash. However, the higher frequency of SAEs and serious infections was observed in the group receiving baricitinib 4 mg.
Study context
- Population
- Patients with active systemic lupus erythematosus (SLE) who did not respond well to standard treatments
- Participants
- 1,849 patients3 randomized controlled trials (RCTs)
- Comparison
- Baricitinib vs placebo
- Placebon = 614reference
- Outcome
- Reduction of ≥ 4 points from baseline in SLEDAI-2K score
Pooled result
As reported in the abstract
Odds ratio
1.407
95% CI 1.123–1.763
P = 0.003
Baricitinib 4 mgvs Placebo
OR 1.407 (95% CI 1.123–1.763); P = 0.003
Further pooled results
| Outcome | OR for SLEDAI-2K remission of arthritis or rash (95% CI) | P value | |
|---|---|---|---|
| SLEDAI-2K remission of arthritis or rashBaricitinib 4 mgvs Placebo | 1.327 (1.059–1.663) | P = 0.014 | |
| 0.512OR for SLEDAI-2K remission of arthritis or rash (log scale) |
Other efficacy outcomes (eg SRI-4 response), baricitinib 4 mg vs placebo
- SRI-4 response and other effectiveness outcomes did not substantially improve with baricitinib 4 mg vs placebo
Efficacy outcomes, baricitinib 2 mg vs placebo
- No significant increase in efficacy outcomes with baricitinib 2 mg vs placebo
Safety
| Outcome | OR (95% CI) | P value | |
|---|---|---|---|
| Severe adverse events (SAE)Baricitinib 4 mgvs Placebo | 1.493 (1.002–2.225) | P = 0.049 | |
| Serious infectionsBaricitinib 4 mgvs Placebo | 2.303 (1.147–4.622) | P = 0.019 | |
| 0.20.5125Odds ratio (log scale) |
Safety outcomes, baricitinib 2 mg
- No differences vs placebo in any safety outcome
Original publication
Treatment of active systemic lupus erythematosus with baricitinib: A meta-analysis of randomized controlled trials. Lupus. Published 18 October 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →